Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
This was a placebo controlled study designed to evaluate the effectiveness of desloratadine
in relieving symptoms of allergic airway disease during the pollen season. Patients received
desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and
side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping
study drug).